Clinical trials / NCT05616221
NCT05616221Phase 2Completed

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Study sponsor: Armata Pharmaceuticals, Inc. · ARMP

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2024-07-17Actual
Enrollment · participants48Actual
Source updated2026-01-05Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: P. aeruginosa recovery in sputum following multiple doses of AP-PA02 administered by inhalation

+ After

Measure: P. Aeruginosa Recovery in Sputum Following Multiple Doses of AP-PA02 Administered by Inhalation

Check registry source